01.11.18
Charles River Laboratories has acquired KWS BioTest, a CRO specializing in in vitro and in vivo discovery testing services for immuno-oncology, inflammatory, and infectious diseases, for approximately $20 million.
The acquisition expands Charles River’s discovery services with additional tools in the growing therapeutic research areas of oncology and immunology. The transaction also includes a potential additional payment of as much as $4 million based on future performance.
James C. Foster, chairman, president and chief executive officer of Charles River, said, “The addition of KWS strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system. In addition to enhancing our position as the premier single-source provider for a broad portfolio of discovery services, KWS increases our ability to support clients’ early-stage drug research in critical therapeutic areas, and expands our geographic footprint in the UK.”
The acquisition expands Charles River’s discovery services with additional tools in the growing therapeutic research areas of oncology and immunology. The transaction also includes a potential additional payment of as much as $4 million based on future performance.
James C. Foster, chairman, president and chief executive officer of Charles River, said, “The addition of KWS strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system. In addition to enhancing our position as the premier single-source provider for a broad portfolio of discovery services, KWS increases our ability to support clients’ early-stage drug research in critical therapeutic areas, and expands our geographic footprint in the UK.”